Biophan Technologies, Inc.Investor Presentation

Michael Weiner, CEO

August 2006

2 •

Safe Harbor Statement

Certain statements included in this presentation may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this presentation should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference.  The forward-looking statements contained herein are made only as of the date of this presentation, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

3 •

Biophan History

• Founded in 2000 by Wilson Greatbatch and Michael Weiner. Wilson Greatbatch is the inventor of the first successful pacemaker, licensed to Medtronic in 1960, and founder of Greatbatch, Inc. NYSE: GB developers of the batteries used in implantable devices.

• Over 200 patents for MRI Safety of devices, Visualization of Stents and Heart Valves, and other innovations for medical devices

• Experienced team from J&J, Angiotech, and Bard

• We intend to change the way patients are treated for cardiovascular diseases and impact a $28 billion market

Current Device Market

5 •

Market for Improved Cardiac Support Devices

Acute Resuscitation $1.1 billionImportant rapid recovery during cardiac emergencies and maintaining cardiac output for short periods of time. Significantly expanded market segment.

Bridge-to-Recovery $1.2 billionProvides short-term support while the heart heals from moderate injury. A very important and growing market.

Bridge-to-Transplant $200 millionKeeps patients alive until a new heart is available.

Destination Therapy $10 billionPermanent support. Huge potential for MYOTECH since other current design VAD problems severely limit usage. Significantly expanded market segment.

Therapeutic Recovery $14 billionLonger-term support from serious disease or injury. The potential for many hearts to recover, allowing device removal. A new market segment.

6 •

$1,887$2,758

$3,749

$4,663

$5,520

$6,468

$7,553$8,526

$0.0

$1,000.0

$2,000.0

$3,000.0

$4,000.0

$5,000.0

$6,000.0

$7,000.0

$8,000.0

$9,000.0

(in m

illion

s)

2001 2002 2003 2004 2005 2006 2007 2008

Worldwide High Power Medical Device Market; Pacemakers, Defibrillators, Neurostimulators

$110

$1,576

$4,013

$5,296$5,574 $5,778 $5,698

$0.0

$1,000.0

$2,000.0

$3,000.0

$4,000.0

$5,000.0

$6,000.0

(in m

illion

s)

2002 2003 2004 2005 2006 2007 2008

Worldwide Drug Coated Stent Market

Large and Growing Markets Need MRI Safe and MRI Visualization Technology

Source: Lehman Brothers Estimates: 12/30/05

Over $12 billion worth of products ship each year that have contraindications or limitations working with MRI.

7 •

The Marketplace (VAD Segment)

Analysts project VAD sales to grow from $400M

(2003) to $7.2B (2009) based upon existing VAD

technologies and their (limited) indications for use.

The total addressable cardiac assist device market

is in excess of

$20 billion.

Source: ABN-AMRO Morgans and SG Cowan

8 •

The Marketplace, cont’d

120 Transplant Centers

960 Specialized Cardiac Centers

Only 61 Active VAD Centers

6800 Hostipals $20B MarketMYOTECH Potential

The technically simple MYO-VAD

promises to expand the market to virtually

ALL hospitals.

Company

10 •

Biophan Overview

• Develop and patent innovations that can move market share between major biomedical device manufacturers

• Completed deal w/ Boston Scientific for $5 Million Equity Investment – both licensing and equity investment provisions – MRI safety and image compatibility

• Committed to making all medical devices safe and imageable under MRI

• Proprietary solutions for– pacemakers– defibrillators and neurostimulators safe with MRI– making stents and heart valves visible under MRI for diagnostics (i.e.:

detecting in-stent restenosis)

• Developing a cardiac support device to overcome the limitations of today’s devices (bleeding, clotting, stroke, infection); it is also MRI safe and image compatible

11 •

Biophan Cardiac Support SystemCompared to Current VAD Technology

Biophan TechnologyExisting VAD Technology

Perforates the heart and great vessels

High risk of patient complications due to clotting and stroke, bleeding, and infection

Average procedure cost: $205,800

Limited applications at specialized transplant and cardiac centers

Simple installation (~3 minutes) and removal

Non-blood contact design promises to provide very low risk of patient complications

Anticipated procedure cost: $60,000

Wide array of applications likely to be available at nearly every community and rural hospital

12 •

The MYO-VAD’s Potential

Dr. James E. Lowe, Professor of Cardiac Surgery and Professor of Pathology at Duke University Medical Center

Please click on the box to run the video.

13 •

Biophan’s Competitive Difference

MYO-VADThoratec

Heartmate II

Worldheart

Novacor

Arrow

CorAide

Ventricor

VenrAssist

BerlinHeart

Incor

No contact with circulating blood

Rapid installation

Systolic and diastolic support

Physiologic pulsatile flow

Support of all size hearts in nearly all disease states

Long-term support destination therapy

Enhance myocardial circulation

Recover from Cardiac Arrest

14 •

Patent Portfolio

• Over 200 U.S. & foreign patents, licenses, or applications

• 56 issued U.S. patents

• Over 100 U.S. pending applications

• Joint Development and License Agreements– Boston Scientific Corp.

• imaging of vascular implants (stents, etc.)

15 •

Patent Portfolio, cont.

Main Patent Focus:• MRI safety for pacemakers, defibrillators,

neurostimulators, guidewires and catheters

• MRI visualization of stents and heart valves, etc.

• Cardiac Support System from Myotech

• Multi-billion dollar markets

• First license with Boston Scientific for imaging of vascular implants (stents, etc.)

16 •

Management Team

• John Lanzafame, COO – former President STS Biopolymers, acquired by Angiotech (ANPI) in 2003

• Jeff Helfer, VP Engineering – formerly Dir. of Engineering with large J&J division, also managed regulatory affairs

• Stu MacDonald, VP R&D – formerly VP R&D at J&J division with a 400 person organization

• Darryl L. Canfield, CPA, VP Finance, Treasurer, Secretary, and CFO – 30-year finance career, formerly with Genencor

• Andreas Melzer, MD, Biophan Europe CTO – Inventor, Radiologist, Surgeon

• Michael Weiner, CEO – formerly of Xerox and has headed several patent related companies

17 •

Board of Directors

• Guenter Jaensch, Ph.D. – former head Siemens Medical, former CEO St. Jude Pacesetter

• Ross Kenzie – headed worldwide sales and marketing at Merrill Lynch and served on board

• Steven Katz – Katz Associates, has run several public companies, formerly with National Patent

• Ted Greenberg – hedge fund manager

• Michael Weiner – co-founder and CEO, Biophan

18 •

Biophan Scientific Advisory Board

Thirteen Scientific Advisors, including:• Cardiovascular Researchers

• University Professors– Biomedical– Biomedical Engineering– Biomedical Imaging– Radiology

• Winner of the Nobel Prize for Chemistry

• Corporate President with over 25 U.S. Patents

• Technology Inventor

19 •

Myotech Advisory Board

Five Board Members, including:• Chief, Division of Cardiothoracic Surgery and Director of

Cardiac Transplantation and Mechanical Support, Associate Professor of Surgery at Ohio State Medical Center

• Associate Professor of Cardiothoracic Surgery at Wright State University of Medicine

• Professor of Cardiac Surgery at Duke University

• Professor of Medicine and Molecular Physiology and Biophysics at Baylor School of Medicine

• Surgical Director of Cardiac Transplantation and LVAD Programs at Duke University

Imaging for Stents and Other Devices

Solutions for Pacemaker Safety

21 •

Today‘s Stents Cannot be Imagedfor Detection of In-Stent Restenosis

Can‘t see inside stents to detect blockage or clotting;

have to perform an angiogram to estimate

blockage.

Biophan technology allows Drs. to look

inside stents to see actual blockage or

clotting.

Resonant Stent

Blockage

22 •

Biophan Allows Detecting Blockage in Vena Cava Filter while using MRI Imaging

Thrombotic blockage is now visible.

Biophan also allows visualization of heart valves.

Active MRI vena cava filter with Biophan technology

Passive MRI vena cava filter; cannot see

inside

Without Biophan

With Biophan

23 •

Biophan Patented Solutions for Pacemaker/Defibrillator Lead Heating

24 •

Biophan Product Sales and Licensing Annuities Add Up to Strong Company

• Cardiac Support System

• Stents, Vena Cava, Heart Valve

• Pacemaker, Defibrillator, Neurostimulator safety

• Multi-Billion $ market potential for advantaged product sold through strategic partner

• $100-$200 million annual annuities

• $40 million license annuities

25 •

Summary

• Closed deal with Boston Scientific in 2005

• MYO-VAD™ advantage

• R&D agreement being developed with Siemens

• CRADA with FDA (May, 2006)

• In negotiations with pacemaker companies for technology licenses for MRI safety

• Heart valve and vena cava filter in development

• Vena Cava filter in animal trials

• Strong management team from J&J and Angiotech

• Strong Scientific Advisory Board

26 •

Biophan Basics

150 Lucius Gordon Drive

West Henrietta, NY 14586

585-214-2441

www.biophan.com

Stock Symbol: OTC: BIPH

Shares Trading: 82,805,243

Average Volume (90-day): 255,525

Investor Relations:Jim Blackman

PR Financial Marketing713-256-0369

jimblackman@prfinancialmarketing.com

Figures as of 8/02/06.